Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors

Trial Profile

Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 May 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Jun 2016 Results from mismatch repair deficiency (MRD) patients (n=29) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2016 Results from a cohort of patients with MMR-deficient non-colorectal cancers (including ampullary/biliary, endometrial, gastric, pancreatic, prostate, sarcoma, and small bowel) and from two cohorts of patients with colorectal cancer (MMR-deficient and MMR-proficient) published in a Merck and Co. media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top